Sugi Predict

Sugi Predict / Compounds / SCHEMBL4584741

SCHEMBL4584741

SCHEMBL4584741

CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 18/20 1.00
▸ CSNK1D P48730 3/20 0.78
▸ MAPK13 O15264 2/20 0.78
▸ MAPK12 P53778 2/20 0.78
▸ MAPK11 Q15759 2/20 0.78
▸ CSNK1E P49674 2/20 0.78
▸ EGFR P00533 1/20 0.78
▸ KCNH2 Q12809 1/20 0.78
▸ RIPK2 O43353 1/20 0.76
▸ DYRK3 O43781 1/20 0.76
▸ PRKD3 O94806 1/20 0.76
▸ MAP4K4 O95819 1/20 0.76
▸ PRKCG P05129 1/20 0.76
▸ LCK P06239 1/20 0.76
▸ LYN P07948 1/20 0.76
▸ RET P07949 1/20 0.76
▸ PIM1 P11309 1/20 0.76
▸ PRKACA P17612 1/20 0.76
▸ MAPK1 P28482 1/20 0.76
▸ FLT4 P35916 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20550753 0.92 MAPK14 (0.91) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL20550893 0.89 MAPK14 (0.98) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL29842083 0.89 MAPK14 (0.98) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL20550876 0.89 MAPK14 (0.93) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL7715289 0.88 MAPK14 (0.79) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL20550488 0.88 MAPK14 (1.00) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL7802983 0.88 MAPK14 (0.83) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL12280165 0.88 MAPK14 (1.00) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL29453495 0.88 MAPK14 (1.00) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL20550928 0.87 MAPK14 (0.77) MAPK14CSNK1DMAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0708768-B1 TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES SMITHKLINE BEECHAM CORP (US) 2003-04-09 — — EP claimed
CN-1050126-C Tri-substituted imidazoles, their preparation and use and pharmaceutical compositions containing them SMITHKLINE BEECHAM CORP (US) 2000-03-08 — — CN claimed
CN-1129447-A Trisubstituted imidazoles having multiple therapeutic effects SMITHKLINE BEECHAM CORP (US) 1996-08-21 — — CN claimed
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS PROTTER ANDREW A 2008-05-08 — — US disclosed
EP-1583535-A4 METHODS FOR TREATING DIABETES SCIOS INC (US) 2008-03-19 — — EP disclosed
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase PROTTER ANDREW A 2008-02-14 — — US disclosed
US-7268139-B2 Methods of promoting osteogenesis SCIOS, INC. (US) 2007-09-11 — — US disclosed
US-7244441-B2 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. (US) 2007-07-17 — — US disclosed
EP-1676574-A2 Methods for promoting survival of transplanted tissues and cells Johnson & Johnson Vision Care, Inc. (US) 2006-07-05 — — EP disclosed
US-20060019971-A1 Treatment of cardiovascular disease with inhibitors of p38 kinase SCIOS INC. 2006-01-26 — — US disclosed
EP-1583535-A2 METHODS FOR TREATING DIABETES SCIOS INC. (US) 2005-10-12 — — EP disclosed
WO-1999018942-A1 USE OF CSAIDTM COMPOUNDS FOR THE MANAGEMENT OF UTERINE CONTRACTIONS IMPERIAL COLLEGE INNOVATIONS LTD. (GB) 1999-04-22 — — WO disclosed
US-5670527-A CYTOKINE INHIBITORS USEFUL IN TREATING ASTHMA, OSTEOPOROSIS, ARTHRITIS, INFLAMMATION, SEPSIS, CARDIOVASCULAR DISORDERS, DIABETES, MULTIPLE SCLEROSIS, SKIN DISORDERS SMITHKLINE BEECHAM CORPORATION (US) 1997-09-23 — — US disclosed
US-5663334-A CYTOKINE INHIBITORS FORMED BY REACTION OF IMINE WITH SULFUR SUBSTITUTED NITRILE SMITHKLINE BEECHAM CORPORATION (US) 1997-09-02 — — US disclosed
US-5593992-A CYTOKINE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1997-01-14 — — US disclosed
US-5593991-A ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR SMITHKLINE BEECHAM CORPORATION 1997-01-14 — — US disclosed
EP-0708768-A4 TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES SMITHKLINE BEECHAM CORP (US) 1996-08-21 — — EP disclosed
CN-1129447-A Trisubstituted imidazoles having multiple therapeutic effects SMITHKLINE BEECHAM CORP (US) 1996-08-21 — — CN disclosed
EP-0708768-A1 TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES SMITHKLINE BEECHAM CORPORATION (US) 1996-05-01 — — EP disclosed
WO-1995002591-A1 TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES SMITHKLINE BEECHAM CORPORATION (US) 1995-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019971-A1 Treatment of cardiovascular disease with inhibitors of p38 kinase MAPKAPK5, MAPK1, MAPKAPK2 MAPK14 36/4885CSNK1D 853/4885MAPK13 34/4885
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS MAPK1, BMP2, MAPK3 MAPK14 23/4885CSNK1D 3484/4885MAPK13 15/4885
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase OPRK1, OPRL1, MAPK3 MAPK14 36/4885CSNK1D 505/4885MAPK13 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.